{"pmid":32387470,"title":"COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome?","text":["COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome?","The severe form of COVID-19 share several clinical and laboratory features with four entities gathered under the term \"hyperferritinemic syndrome\" and including macrophage activation syndrome (MAS), adult-onset Still's disease (AOSD), catastrophic anti-phospholipid syndrome (CAPS) and septic shock. COVID-19 systemic inflammatory reaction and \"hyperferritinemic syndromes\" are all characterized by high serum ferritin and a life-threatening hyper-inflammation sustained by a cytokines storm which eventually leads to multi-organ failure. In this review, we analyze the possible epidemiological and molecular mechanisms responsible for hyper-inflammation in patients with severe COVID-19 and we underline the similarities between this condition and \"hyperferritinemic syndromes\" which would allow considering this entity as the fifth member of the spectrum of inflammatory conditions.","Autoimmun Rev","Colafrancesco, Serena","Alessandri, Cristiano","Conti, Fabrizio","Priori, Roberta","32387470"],"abstract":["The severe form of COVID-19 share several clinical and laboratory features with four entities gathered under the term \"hyperferritinemic syndrome\" and including macrophage activation syndrome (MAS), adult-onset Still's disease (AOSD), catastrophic anti-phospholipid syndrome (CAPS) and septic shock. COVID-19 systemic inflammatory reaction and \"hyperferritinemic syndromes\" are all characterized by high serum ferritin and a life-threatening hyper-inflammation sustained by a cytokines storm which eventually leads to multi-organ failure. In this review, we analyze the possible epidemiological and molecular mechanisms responsible for hyper-inflammation in patients with severe COVID-19 and we underline the similarities between this condition and \"hyperferritinemic syndromes\" which would allow considering this entity as the fifth member of the spectrum of inflammatory conditions."],"journal":"Autoimmun Rev","authors":["Colafrancesco, Serena","Alessandri, Cristiano","Conti, Fabrizio","Priori, Roberta"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32387470","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.autrev.2020.102573","keywords":["covid-19","cytokine storm","ferritin","inflammation"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666428892708077568,"score":9.490897,"similar":[{"pmid":32423970,"title":"Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin.","text":["Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin.","Some of the articles being published during the severe acute respiratory syndrome-coronavirus (SARS-CoV)-2 pandemic highlight a link between severe forms of coronavirus disease 2019 (COVID-19) and the so-called cytokine storm, also with increased ferritin levels. However, this scenario is more complex than initially thought due to the heterogeneity of hyperinflammation. Some patients with coronavirus 2019 disease (COVID-19) develop a fully blown secondary haemophagocytic lymphohistiocytosis (sHLH), whereas others, despite a consistent release of pro-inflammatory cytokines, do not fulfil sHLH criteria but still show some features resembling the phenotype of the hyperferritinemic syndrome. Despite the final event (the cytokine storm) is shared by various conditions leading to sHLH, the aetiology, either infectious, autoimmune or neoplastic, accounts for the differences in the various phases of this process. Moreover, the evidence of a hyperinflammatory microenvironment provided the rationale to employ immunomodulating agents for therapeutic purposes in severe COVID-19. This viewpoint aims at discussing the pitfalls and issues to be considered with regard to the use of immunomodulating agents in COVID-19, such as timing of treatment based on the viral load and the extent of cytokine/ferritin overexpression. Furthermore, it encompasses recent findings in the paediatric field about a novel multisystem inflammatory disease resembling toxic shock syndrome and atypical Kawasaki disease observed in children with proven SARS-CoV2 infection. Finally, it includes arguments in favour of adding COVID-19 to the spectrum of the recently defined 'hyperferritinemic syndrome', which already includes adult-onset Still's disease, macrophage activation syndrome, septic shock and catastrophic anti-phospholipid syndrome.","RMD Open","Alunno, Alessia","Carubbi, Francesco","Rodriguez-Carrio, Javier","32423970"],"abstract":["Some of the articles being published during the severe acute respiratory syndrome-coronavirus (SARS-CoV)-2 pandemic highlight a link between severe forms of coronavirus disease 2019 (COVID-19) and the so-called cytokine storm, also with increased ferritin levels. However, this scenario is more complex than initially thought due to the heterogeneity of hyperinflammation. Some patients with coronavirus 2019 disease (COVID-19) develop a fully blown secondary haemophagocytic lymphohistiocytosis (sHLH), whereas others, despite a consistent release of pro-inflammatory cytokines, do not fulfil sHLH criteria but still show some features resembling the phenotype of the hyperferritinemic syndrome. Despite the final event (the cytokine storm) is shared by various conditions leading to sHLH, the aetiology, either infectious, autoimmune or neoplastic, accounts for the differences in the various phases of this process. Moreover, the evidence of a hyperinflammatory microenvironment provided the rationale to employ immunomodulating agents for therapeutic purposes in severe COVID-19. This viewpoint aims at discussing the pitfalls and issues to be considered with regard to the use of immunomodulating agents in COVID-19, such as timing of treatment based on the viral load and the extent of cytokine/ferritin overexpression. Furthermore, it encompasses recent findings in the paediatric field about a novel multisystem inflammatory disease resembling toxic shock syndrome and atypical Kawasaki disease observed in children with proven SARS-CoV2 infection. Finally, it includes arguments in favour of adding COVID-19 to the spectrum of the recently defined 'hyperferritinemic syndrome', which already includes adult-onset Still's disease, macrophage activation syndrome, septic shock and catastrophic anti-phospholipid syndrome."],"journal":"RMD Open","authors":["Alunno, Alessia","Carubbi, Francesco","Rodriguez-Carrio, Javier"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32423970","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1136/rmdopen-2020-001295","keywords":["atherosclerosis","autoantibodies","cytokines","early rheumatoid arthritis","inflammation","rheumatoid arthritis","sjogren's syndrome","t cells"],"locations":["Kawasaki","typhoon"],"countries":["Japan"],"countries_codes":["JPN|Japan"],"topics":["Treatment"],"weight":1,"_version_":1667352728904400899,"score":427.13287},{"pmid":32251717,"pmcid":"PMC7195002","title":"The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease.","text":["The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease.","Severe COVID-19 associated pneumonia patients may exhibit features of systemic hyper-inflammation designated under the umbrella term of macrophage activation syndrome (MAS) or cytokine storm, also known as secondary haemophagocytic lymphohistocytosis (sHLH). This is distinct from HLH associated with immunodeficiency states termed primary HLH -with radically different therapy strategies in both situations. COVID-19 infection with MAS typically occurs in subjects with adult respiratory distress syndrome (ARDS) and historically, non-survival in ARDS was linked to sustained IL-6 and IL-1 elevation. We provide a model for the classification of MAS to stratify the MAS-like presentation in COVID-19 pneumonia and explore the complexities of discerning ARDS from MAS. We discuss the potential impact of timing of anti-cytokine therapy on viral clearance and the impact of such therapy on intra-pulmonary macrophage activation and emergent pulmonary vascular disease.","Autoimmun Rev","McGonagle, Dennis","Sharif, Kassem","O'Regan, Anthony","Bridgewood, Charlie","32251717"],"abstract":["Severe COVID-19 associated pneumonia patients may exhibit features of systemic hyper-inflammation designated under the umbrella term of macrophage activation syndrome (MAS) or cytokine storm, also known as secondary haemophagocytic lymphohistocytosis (sHLH). This is distinct from HLH associated with immunodeficiency states termed primary HLH -with radically different therapy strategies in both situations. COVID-19 infection with MAS typically occurs in subjects with adult respiratory distress syndrome (ARDS) and historically, non-survival in ARDS was linked to sustained IL-6 and IL-1 elevation. We provide a model for the classification of MAS to stratify the MAS-like presentation in COVID-19 pneumonia and explore the complexities of discerning ARDS from MAS. We discuss the potential impact of timing of anti-cytokine therapy on viral clearance and the impact of such therapy on intra-pulmonary macrophage activation and emergent pulmonary vascular disease."],"journal":"Autoimmun Rev","authors":["McGonagle, Dennis","Sharif, Kassem","O'Regan, Anthony","Bridgewood, Charlie"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251717","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.autrev.2020.102537","locations":["Pneumonia"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138491010940928,"score":232.88535},{"pmid":32320677,"pmcid":"PMC7172841","title":"Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure.","text":["Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure.","Proper management of COVID-19 mandates better understanding of disease pathogenesis. The sudden clinical deterioration 7-8 days after initial symptom onset suggests that severe respiratory failure (SRF) in COVID-19 is driven by a unique pattern of immune dysfunction. We studied immune responses of 54 COVID-19 patients, 28 of whom had SRF. All patients with SRF displayed either macrophage activation syndrome (MAS) or very low human leukocyte antigen D related (HLA-DR) expression accompanied by profound depletion of CD4 lymphocytes, CD19 lymphocytes, and natural killer (NK) cells. Tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) production by circulating monocytes was sustained, a pattern distinct from bacterial sepsis or influenza. SARS-CoV-2 patient plasma inhibited HLA-DR expression, and this was partially restored by the IL-6 blocker Tocilizumab; off-label Tocilizumab treatment of patients was accompanied by increase in circulating lymphocytes. Thus, the unique pattern of immune dysregulation in severe COVID-19 is characterized by IL-6-mediated low HLA-DR expression and lymphopenia, associated with sustained cytokine production and hyper-inflammation.","Cell Host Microbe","Giamarellos-Bourboulis, Evangelos J","Netea, Mihai G","Rovina, Nikoletta","Akinosoglou, Karolina","Antoniadou, Anastasia","Antonakos, Nikolaos","Damoraki, Georgia","Gkavogianni, Theologia","Adami, Maria-Evangelia","Katsaounou, Paraskevi","Ntaganou, Maria","Kyriakopoulou, Magdalini","Dimopoulos, George","Koutsodimitropoulos, Ioannis","Velissaris, Dimitrios","Koufargyris, Panagiotis","Karageorgos, Athanassios","Katrini, Konstantina","Lekakis, Vasileios","Lupse, Mihaela","Kotsaki, Antigone","Renieris, George","Theodoulou, Danai","Panou, Vassiliki","Koukaki, Evangelia","Koulouris, Nikolaos","Gogos, Charalambos","Koutsoukou, Antonia","32320677"],"abstract":["Proper management of COVID-19 mandates better understanding of disease pathogenesis. The sudden clinical deterioration 7-8 days after initial symptom onset suggests that severe respiratory failure (SRF) in COVID-19 is driven by a unique pattern of immune dysfunction. We studied immune responses of 54 COVID-19 patients, 28 of whom had SRF. All patients with SRF displayed either macrophage activation syndrome (MAS) or very low human leukocyte antigen D related (HLA-DR) expression accompanied by profound depletion of CD4 lymphocytes, CD19 lymphocytes, and natural killer (NK) cells. Tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) production by circulating monocytes was sustained, a pattern distinct from bacterial sepsis or influenza. SARS-CoV-2 patient plasma inhibited HLA-DR expression, and this was partially restored by the IL-6 blocker Tocilizumab; off-label Tocilizumab treatment of patients was accompanied by increase in circulating lymphocytes. Thus, the unique pattern of immune dysregulation in severe COVID-19 is characterized by IL-6-mediated low HLA-DR expression and lymphopenia, associated with sustained cytokine production and hyper-inflammation."],"journal":"Cell Host Microbe","authors":["Giamarellos-Bourboulis, Evangelos J","Netea, Mihai G","Rovina, Nikoletta","Akinosoglou, Karolina","Antoniadou, Anastasia","Antonakos, Nikolaos","Damoraki, Georgia","Gkavogianni, Theologia","Adami, Maria-Evangelia","Katsaounou, Paraskevi","Ntaganou, Maria","Kyriakopoulou, Magdalini","Dimopoulos, George","Koutsodimitropoulos, Ioannis","Velissaris, Dimitrios","Koufargyris, Panagiotis","Karageorgos, Athanassios","Katrini, Konstantina","Lekakis, Vasileios","Lupse, Mihaela","Kotsaki, Antigone","Renieris, George","Theodoulou, Danai","Panou, Vassiliki","Koukaki, Evangelia","Koulouris, Nikolaos","Gogos, Charalambos","Koutsoukou, Antonia"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320677","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.chom.2020.04.009","keywords":["covid-19","hla-dr","sars-cov-2","dysregulation","ferritin","interleukin-6","lymphopenia","macrophage activation","monocytes","respiratory failure"],"e_drugs":["tocilizumab"],"topics":["Treatment"],"weight":1,"_version_":1666138493718364161,"score":213.41052},{"pmid":32387301,"title":"The CoV-2 outbreak: how hematologists could help to fight Covid-19.","text":["The CoV-2 outbreak: how hematologists could help to fight Covid-19.","COVID-19 is a medical emergency, with 20 % of patients presenting with severe clinical manifestations. From the pathogenetic point of view, COVID-19 mimics two other well-known diseases characterized by cytokine storm and hyper-activation of the immune response, with consequent organ damage: acute graft-versus-host disease (aGVHD) and macrophage activation syndrome (MAS). Hematologists are confident with these situations requiring a prompt therapeutic approach for switching off the uncontrolled cytokine release; here, we discuss pros and cons of drugs that are already employed in hematology in the light of their possible application in COVID-19. The most promising drugs might be: Ruxolitinib, a JAK1/2 inhibitor, with a rapid and powerful anti-cytokine effect, tyrosine kinase inhibitors (TKIs), with their good anti-inflammatory properties, and perhaps the anti-Cd26 antibody Begelomab. We also present immunological data from gene expression experiments where TKIs resulted effective anti-inflammatory and pro-immune drugs. A possible combined treatment algorithm for COVID-19 is here proposed.","Pharmacol Res","Galimberti, Sara","Baldini, Chiara","Barate, Claudia","Ricci, Federica","Balducci, Serena","Grassi, Susanna","Ferro, Francesco","Buda, Gabriele","Benedetti, Edoardo","Fazzi, Rita","Baglietto, Laura","Lucenteforte, Ersilia","Di Paolo, Antonello","Petrini, Mario","32387301"],"abstract":["COVID-19 is a medical emergency, with 20 % of patients presenting with severe clinical manifestations. From the pathogenetic point of view, COVID-19 mimics two other well-known diseases characterized by cytokine storm and hyper-activation of the immune response, with consequent organ damage: acute graft-versus-host disease (aGVHD) and macrophage activation syndrome (MAS). Hematologists are confident with these situations requiring a prompt therapeutic approach for switching off the uncontrolled cytokine release; here, we discuss pros and cons of drugs that are already employed in hematology in the light of their possible application in COVID-19. The most promising drugs might be: Ruxolitinib, a JAK1/2 inhibitor, with a rapid and powerful anti-cytokine effect, tyrosine kinase inhibitors (TKIs), with their good anti-inflammatory properties, and perhaps the anti-Cd26 antibody Begelomab. We also present immunological data from gene expression experiments where TKIs resulted effective anti-inflammatory and pro-immune drugs. A possible combined treatment algorithm for COVID-19 is here proposed."],"journal":"Pharmacol Res","authors":["Galimberti, Sara","Baldini, Chiara","Barate, Claudia","Ricci, Federica","Balducci, Serena","Grassi, Susanna","Ferro, Francesco","Buda, Gabriele","Benedetti, Edoardo","Fazzi, Rita","Baglietto, Laura","Lucenteforte, Ersilia","Di Paolo, Antonello","Petrini, Mario"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32387301","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.phrs.2020.104866","keywords":["baricitinib","begelomab","covid-19","gvhd","mas","ruxolitinib","tkis","tocilizumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666428892704931840,"score":192.15201},{"pmid":32385712,"title":"Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?","text":["Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?","Severe coronavirus disease (COVID-19) is characterized by pulmonary hyper-inflammation and potentially life-threatening \"cytokine storms\". Controlling the local and systemic inflammatory response in COVID-19 may be as important as anti-viral therapies. Endogenous lipid autacoid mediators, referred to as eicosanoids, play a critical role in the induction of inflammation and pro-inflammatory cytokine production. SARS-CoV-2 may trigger a cell death (\"debris\")-induced \"eicosanoid storm\", including prostaglandins and leukotrienes, which in turn initiates a robust inflammatory response. A paradigm shift is emerging in our understanding of the resolution of inflammation as an active biochemical process with the discovery of novel endogenous specialized pro-resolving lipid autacoid mediators (SPMs), such as resolvins. Resolvins and other SPMs stimulate macrophage-mediated clearance of debris and counter pro-inflammatory cytokine production, a process called inflammation resolution. SPMs and their lipid precursors exhibit anti-viral activity at nanogram doses in the setting of influenza without being immunosuppressive. SPMs also promote anti-viral B cell antibodies and lymphocyte activity, highlighting their potential use in the treatment of COVID-19. Soluble epoxide hydrolase (sEH) inhibitors stabilize arachidonic acid-derived epoxyeicosatrienoic acids (EETs), which also stimulate inflammation resolution by promoting the production of pro-resolution mediators, activating anti-inflammatory processes, and preventing the cytokine storm. Both resolvins and EETs also attenuate pathological thrombosis and promote clot removal, which is emerging as a key pathology of COVID-19 infection. Thus, both SPMs and sEH inhibitors may promote the resolution of inflammation in COVID-19, thereby reducing acute respiratory distress syndrome (ARDS) and other life-threatening complications associated with robust viral-induced inflammation. While most COVID-19 clinical trials focus on \"anti-viral\" and \"anti-inflammatory\" strategies, stimulating inflammation resolution is a novel host-centric therapeutic avenue. Importantly, SPMs and sEH inhibitors are currently in clinical trials for other inflammatory diseases and could be rapidly translated for the management of COVID-19 via debris clearance and inflammatory cytokine suppression. Here, we discuss using pro-resolution mediators as a potential complement to current anti-viral strategies for COVID-19.","Cancer Metastasis Rev","Panigrahy, Dipak","Gilligan, Molly M","Huang, Sui","Gartung, Allison","Cortes-Puch, Irene","Sime, Patricia J","Phipps, Richard P","Serhan, Charles N","Hammock, Bruce D","32385712"],"abstract":["Severe coronavirus disease (COVID-19) is characterized by pulmonary hyper-inflammation and potentially life-threatening \"cytokine storms\". Controlling the local and systemic inflammatory response in COVID-19 may be as important as anti-viral therapies. Endogenous lipid autacoid mediators, referred to as eicosanoids, play a critical role in the induction of inflammation and pro-inflammatory cytokine production. SARS-CoV-2 may trigger a cell death (\"debris\")-induced \"eicosanoid storm\", including prostaglandins and leukotrienes, which in turn initiates a robust inflammatory response. A paradigm shift is emerging in our understanding of the resolution of inflammation as an active biochemical process with the discovery of novel endogenous specialized pro-resolving lipid autacoid mediators (SPMs), such as resolvins. Resolvins and other SPMs stimulate macrophage-mediated clearance of debris and counter pro-inflammatory cytokine production, a process called inflammation resolution. SPMs and their lipid precursors exhibit anti-viral activity at nanogram doses in the setting of influenza without being immunosuppressive. SPMs also promote anti-viral B cell antibodies and lymphocyte activity, highlighting their potential use in the treatment of COVID-19. Soluble epoxide hydrolase (sEH) inhibitors stabilize arachidonic acid-derived epoxyeicosatrienoic acids (EETs), which also stimulate inflammation resolution by promoting the production of pro-resolution mediators, activating anti-inflammatory processes, and preventing the cytokine storm. Both resolvins and EETs also attenuate pathological thrombosis and promote clot removal, which is emerging as a key pathology of COVID-19 infection. Thus, both SPMs and sEH inhibitors may promote the resolution of inflammation in COVID-19, thereby reducing acute respiratory distress syndrome (ARDS) and other life-threatening complications associated with robust viral-induced inflammation. While most COVID-19 clinical trials focus on \"anti-viral\" and \"anti-inflammatory\" strategies, stimulating inflammation resolution is a novel host-centric therapeutic avenue. Importantly, SPMs and sEH inhibitors are currently in clinical trials for other inflammatory diseases and could be rapidly translated for the management of COVID-19 via debris clearance and inflammatory cytokine suppression. Here, we discuss using pro-resolution mediators as a potential complement to current anti-viral strategies for COVID-19."],"journal":"Cancer Metastasis Rev","authors":["Panigrahy, Dipak","Gilligan, Molly M","Huang, Sui","Gartung, Allison","Cortes-Puch, Irene","Sime, Patricia J","Phipps, Richard P","Serhan, Charles N","Hammock, Bruce D"],"date":"2020-05-10T11:00:00Z","year":2020,"_id":"32385712","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1007/s10555-020-09889-4","keywords":["covid-19","cytokine storms","eicosanoid storm","inflammation resolution","sars-cov-2"],"e_drugs":["Eicosanoids","Arachidonic Acid","Lipids","Prostaglandins","Leukotrienes"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666340102065881089,"score":190.7078}]}